Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial
Journal of Clinical Oncology · 20.03.2025 · 43 (9) · 1101-1112
DOI: 10.1200/jco-24-02086 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.03.2025. Verfasst von Kevin Kalinsky und 22 weiteren Autor:innen. Beteiligte Einrichtung: Winship Cancer Institute at Emory University, Atlanta, GA. Hauptthemen laut MEDLINE: Fulvestrant, Aminopyridines, Breast Neoplasms, Benzimidazoles. Die Arbeit wurde bisher 109-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) are the standard first-line treatment for hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC); however, disease progression occurs in almost all patients and additional treatment options are needed. Herein, we report outcomes of the postMONARCH trial investigating a switch in ET with/without CDK4/6 inhibition with abemaciclib after disease progression on CDK4/6i. METHODS This double-blind, randomized phase III study enrolled patients with disease progression on previous CDK4/6i plus aromatase inhibitor as initial therapy for advanced disease or recurrence on/after adjuvant CDK4/6i + ET. Patients were randomly assigned (1:1) to abemaciclib + fulvestrant or placebo + fulvestrant. The primary end point was investigator-assessed progression-free survival (PFS). Secondary end points included PFS by blinded independent central review, objective response rate (ORR), and safety. RESULTS This study randomly assigned 368 patients (abemaciclib + fulvestrant, n = 182 placebo + fulvestrant, n = 186). At the primary analysis (258 events), the hazard ratio (HR) was 0.73 (95% CI, 0.57 to 0.95; nominal P = .017), with median PFS 6.0 (95% CI, 5.6 to 8.6) versus 5.3 (95% CI, 3.7 to 5.6) months and 6-month PFS rates of 50% and 37% in the abemaciclib + fulvestrant and placebo + fulvestrant arms, respectively. These results were supported by BICR-assessed PFS (HR, 0.55 [95% CI, 0.39 to 0.77]; nominal P < .001). A consistent treatment effect was seen across major clinical and genomic subgroups, including with/without ESR1 or PIK3CA mutations. Among patients with measurable disease, investigator-assessed ORR was improved with abemaciclib + fulvestrant versus placebo + fulvestrant (17% v 7%; nominal P = .015). No new safety signals were observed, with findings consistent with the known safety profile of abemaciclib. CONCLUSION Abemaciclib + fulvestrant significantly improved PFS after disease progression on previous CDK4/6i + ET in patients with HR+, HER2– ABC, offering an additional targeted therapy option for these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Winship Cancer Institute at Emory University, Atlanta, GA.
- IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.
- Sarah Cannon Research Institute, Nashville, TN.
- Brown University Health, Legorreta Cancer Center at Brown University, Providence, RI.
- Korea University Anam Hospital, Korea University, Seoul, South Korea.
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
ORCID-Profile: Kevin Kalinsky, Giampaolo Bianchini, Erika Hamilton, Stephanie L Graff, Kyong Hwa Park, Rinath Jeselsohn, Miguel Martin, Rachel M Layman, Sara A Hurvitz, Sarah Sammons, Peter A Kaufman, Montserrat Muñoz, Bastien Nguyen, Yanhong Zhou, Elizabeth Ravenberg, Lillian Smyth, Seth A Wander
Zitieren
APA
Kalinsky, K., Bianchini, G., Hamilton, E., Graff, S. L., Park, K. H., Jeselsohn, R., Demirci, U., Martin, M., Layman, R. M., Hurvitz, S. A., Sammons, S., Kaufman, P. A., Muñoz, M., Lai, J. I., Knoderer, H., Sandoval, C., Chawla, A. R., Nguyen, B., Zhou, Y., …, & Wander, S. A. (2025). Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial. Journal of Clinical Oncology, 43(9), 1101-1112. https://doi.org/10.1200/jco-24-02086
Vancouver
Kalinsky K, Bianchini G, Hamilton E, Graff SL, Park KH, Jeselsohn R, et al. Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial. Journal of Clinical Oncology. 2025;43(9):1101-1112. doi:10.1200/jco-24-02086
BibTeX
@article{Kalinsky2025,
author = {Kalinsky, Kevin and Bianchini, Giampaolo and Hamilton, Erika and Graff, Stephanie L and Park, Kyong Hwa and Jeselsohn, Rinath and Demirci, Umut and Martin, Miguel and Layman, Rachel M and Hurvitz, Sara A and Sammons, Sarah and Kaufman, Peter A and Muñoz, Montserrat and Lai, Jiun-I and Knoderer, Holly and Sandoval, Cynthia and Chawla, Aarti R and Nguyen, Bastien and Zhou, Yanhong and Ravenberg, Elizabeth and Litchfield, Lacey M and Smyth, Lillian and Wander, Seth A},
title = {Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {9},
pages = {1101--1112},
doi = {10.1200/jco-24-02086}
}
EUVIMED